Novel immunotherapeutic approaches to glioma.
Despite advances in radiation, chemotherapy and surgical resectioning, the prognosis of patients with malignant glioma is poor. Therefore, the development of a new treatment modality is extremely important. There are an increasing number of reports that systemic immunotherapy using dendritic cells and peptides is capable of inducing an anti-glioma response. This review highlights progress in dendritic cell- and peptide-based immunotherapy for glioma patients. Dendritic cell- and peptide-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma; the therapy appears to be safe and without major side effects. Biotherapy for malignant glioma with dendritic cells and peptides represents a novel treatment paradigm.
Yamanaka
Ryuya
R
Niigata University, Brain Research Institute, Department of Neurosurgery, Asahimachi-dori 1-757, Niigata City 951-8585, Japan. ryaman@bri.niigata-u.ac.jp
D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology; D005910:Glioma / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines